Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 years.
Histological confirmation of primary breast cancer.
Patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development of 1-3 extracranial sites of oligoprogressive disease, and who plan for the continuation of the current systemic therapy.
OR
Exclusion criteria
Male patients.
Nursing or pregnant women.
Men or women of childbearing potential who are unwilling to employ adequate contraception.
Patients with triple negative disease (negative for ER, PR, and HER2).
Active second primary malignancy
> 3 extracranial sites of oligoprogressive disease
Active CNS disease. Patients with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed.
Active connective tissue disease that is felt by the treatment team to pose an excess risk of toxicity.
Prior radiation that overlaps with the intended treatment volume such that, in the opinion of the patient's Radiation Oncologist, radiotherapy to progressing sites will not be safe.
Primary purpose
Allocation
Interventional model
Masking
45 participants in 1 patient group
Loading...
Central trial contact
Clinical Trials Referral Office
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal